# A Study of TAVO412 in Patients with Cancer (TAVO412)

> **NCT06761651** · PHASE1 · RECRUITING · sponsor: **Tavotek Biotherapeutics** · enrollment: 50 (estimated)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** TAVO412

## Key facts

- **NCT ID:** NCT06761651
- **Lead sponsor:** Tavotek Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-20
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-10-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06761651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06761651, "A Study of TAVO412 in Patients with Cancer (TAVO412)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06761651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*